4.2 Article

Longitudinal Trajectories of Informant-Reported Daily Functioning in Empirically Defined Subtypes of Mild Cognitive Impairment

Journal

Publisher

CAMBRIDGE UNIV PRESS
DOI: 10.1017/S1355617717000285

Keywords

Instrumental activities of daily living; MCI; Dementia; Alzheimer's disease; Executive functioning; Functional activities questionnaire; longitudinal

Funding

  1. NIH [R01 AG049810, K24 AG026431]
  2. U.S. Department of Veterans Affairs Clinical Sciences Research and Development Service [1IK2 CX001415-01A1]
  3. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  4. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  5. National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering
  6. AbbVie
  7. Alzheimer's Association
  8. Alzheimer's Drug Discovery Foundation
  9. Araclon Biotech
  10. BioClinica, Inc.
  11. Biogen
  12. Bristol-Myers Squibb Company
  13. CereSpir, Inc.
  14. Cogstate
  15. Eisai Inc.
  16. Elan Pharmaceuticals, Inc.
  17. Eli Lilly and Company
  18. EuroImmun
  19. F. Hoffmann-La Roche Ltd
  20. Genentech, Inc.
  21. Fujirebio
  22. GE Healthcare
  23. IXICO Ltd.
  24. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  25. Johnson & Johnson Pharmaceutical Research & Development LLC.
  26. Lumosity
  27. Lundbeck
  28. Merck Co., Inc.
  29. Meso Scale Diagnostics, LLC.
  30. NeuroRx Research
  31. Neurotrack Technologies
  32. Novartis Pharmaceuticals Corporation
  33. Pfizer Inc.
  34. Piramal Imaging
  35. Servier
  36. Takeda Pharmaceutical Company
  37. Transition Therapeutics
  38. Canadian Institutes of Health Research

Ask authors/readers for more resources

Objectives: Within the Alzheimer's Disease Neuroimaging Initiative (ADNI)'s mild cognitive impairment (MCI) cohort, we previously identified MCI subtypes as well as participants initially diagnosed with MCI but found to have normal neuropsychological, biomarker, and neuroimaging profiles. We investigated the functional change over time in these empirically derived MCI subgroups. Methods: ADNI MCI participants (n=654) were classified using cluster analysis as Amnestic MCI (single-domain memory impairment), Dysnomic MCI (memory+language impairments), Dysexecutive/Mixed MCI (memory+language+attention/executive impairments), or Cluster-Derived Normal (CDN). Robust normal control participants (NCs; n=284) were also examined. The Functional Activities Questionnaire (FAQ) was administered at baseline through 48-month follow-up. Multilevel modeling examined FAQ trajectories by cognitive subgroup. Results: The Dysexecutive/Mixed group demonstrated the fastest rate of decline across all groups. Amnestic and Dysnomic groups showed steeper rates of decline than CDNs. While CDNs had more functional difficulty than NCs across visits, both groups' mean FAQ scores remained below its suggested cutoff at all visits. Conclusions: Results (a) show the importance of executive dysfunction in the context of other impaired cognitive domains when predicting functional decline in at-risk elders, and (b) support our previous work demonstrating that ADNI's MCI criteria may have resulted in false-positive MCI diagnoses, given the CDN's better FAQ trajectory than those of the cognitively impaired MCI groups.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available